Krüger Vitória Machado, da Silva Alexandre Lemos, Goldani Luciano Zubaran
Universidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Ciências Médicas, Porto Alegre, RS, Brazil; Secretaria da Saúde do Estado do Rio Grande do Sul, Centro Estadual de Vigilância em Saúde, Porto Alegre, RS, Brazil.
Secretaria da Saúde do Estado do Rio Grande do Sul, Centro Estadual de Vigilância em Saúde, Porto Alegre, RS, Brazil; Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Braz J Infect Dis. 2025 Aug 28;29(5):104575. doi: 10.1016/j.bjid.2025.104575.
Hepatitis B remains a global health concern due its high prevalence and association with chronic liver disease. Although vaccination is safe and effective in immunocompetent individuals, patients with hematological malignancies often exhibit immune dysfunction and reduced vaccine responses, increasing their susceptibility to vaccine-preventable infections. This study aimed to assess the hepatitis B vaccination status and immunoprotection in pediatric oncology patients treated at a tertiary public hospital in southern Brazil. A retrospective, single-center study was conducted with patients aged 0 to 15 years undergoing treatment for hematological malignancies between 2020 and 2022. Clinical and demographic data were obtained from electronic medical records, including vaccination history and hepatitis B serology profile. Vaccination status was verified through the National Immunization Program Information System. A total of 101 patients were evaluated, comprising 58 (57.4 %) males and 43 (42.6 %) females. The predominant diagnosis was acute lymphoblastic leukemia, reported in 67 cases (66.3 %). All patients underwent chemotherapy protocols, and 28 (27.7 %) died during the study period. Serological data for hepatitis B were available for 66 patients (65.3 %), with the highest proportions of missing data for anti-HBs (25.7 %) and total anti-HBc (13.9 %). None tested positive for HBsAg, 2 (2.3 %) were positive for total anti-HBc and 33 (44.0 %) for anti-HBs. Regarding vaccination status, 62 (61.4 %) had completed the hepatitis B vaccine series, 12 (11.9 %) had incomplete schedules, and 27 (26.7 %) had no records available. Only 10 patients (13.5 %) received additional vaccination after oncological diagnosis. Among those with a complete vaccination schedule, 27 (55.1 %) did not develop protective antibodies. These findings demonstrate low level of immunoprotection and suboptimal vaccine coverage against hepatitis B in this population. Optimizing vaccination protocols and monitoring strategies are essential to ensure adequate immunization against hepatitis B and other preventable diseases in immunosuppressed pediatric patients receiving care in Brazil.
由于乙肝的高流行率及其与慢性肝病的关联,它仍然是一个全球关注的健康问题。尽管疫苗接种在免疫功能正常的个体中是安全有效的,但血液系统恶性肿瘤患者通常存在免疫功能障碍且疫苗反应降低,这增加了他们对疫苗可预防感染的易感性。本研究旨在评估巴西南部一家三级公立医院治疗的儿科肿瘤患者的乙肝疫苗接种状况和免疫保护情况。对2020年至2022年间年龄在0至15岁接受血液系统恶性肿瘤治疗的患者进行了一项回顾性单中心研究。从电子病历中获取临床和人口统计学数据,包括疫苗接种史和乙肝血清学特征。通过国家免疫规划信息系统核实疫苗接种状况。共评估了101例患者,其中男性58例(57.4%),女性43例(42.6%)。主要诊断为急性淋巴细胞白血病,67例(66.3%)报告为此病。所有患者均接受化疗方案,28例(27.7%)在研究期间死亡。66例患者(65.3%)有乙肝血清学数据,抗-HBs(25.7%)和总抗-HBc(13.9%)缺失数据比例最高。无一例HBsAg检测呈阳性,2例(2.3%)总抗-HBc呈阳性,33例(44.0%)抗-HBs呈阳性。关于疫苗接种状况,62例(61.4%)完成了乙肝疫苗系列接种,12例(11.9%)接种计划不完整,27例(26.7%)无可用记录。只有十名患者(13.5%)在肿瘤诊断后接受了额外接种。在完成接种计划的患者中,27例(55.1%)未产生保护性抗体。这些发现表明该人群中针对乙肝的免疫保护水平较低且疫苗接种覆盖率未达最佳。优化疫苗接种方案和监测策略对于确保巴西接受治疗的免疫抑制儿科患者获得足够的乙肝及其他可预防疾病的免疫接种至关重要。